REL and hepatocellular carcinoma: For example, DDR2 can drive sorafenib resistance by the NF-κB/c-Rel signaling pathway in HCC [42], while ABCC5 promotes sorafenib resistance by inhibiting SLC7A11-induced ferroptosis in HCC [43].